Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Erasca (Nasdaq: ERAS) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management will present on Tuesday, January 13, 2026 at 1:30 PM PT, participate in one-on-one investor meetings, and provide a live audio webcast at Erasca.com/events. An archived replay will be available for 30 days after the webcast.
Positive
- None.
Negative
- None.
News Market Reaction – ERAS
On the day this news was published, ERAS gained 4.01%, reflecting a moderate positive market reaction. Argus tracked a peak move of +72.2% during that session. Our momentum scanner triggered 62 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $70M to the company's valuation, bringing the market cap to $1.81B at that time. Trading volume was exceptionally heavy at 15.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ERAS was down 2.79% while key peer ALMS showed strong upside momentum of 93.26%, suggesting ERAS trading was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conference | Positive | +6.2% | Evercore healthcare conference fireside chat and webcast announcement. |
| Nov 12 | Earnings update | Positive | +12.3% | Q3 2025 business update, patent issuance, cash runway into H2 2028. |
| Nov 06 | Patent issuance | Positive | +1.8% | U.S. patent issued covering pan‑RAS molecular glue ERAS‑0015. |
| Nov 04 | Conference schedule | Neutral | -2.9% | Multiple November 2025 investor conferences and fireside chats. |
| Sep 02 | Investor conference | Neutral | +1.9% | Morgan Stanley global healthcare conference presentation and meetings. |
ERAS often reacted positively to earnings and many conference-related updates, though some conference appearances produced muted or negative moves.
Over the past few months, Erasca has repeatedly highlighted its participation in major healthcare conferences and investor events, along with patent and earnings updates. An August 2025 strategic and financial update and a November 2025 earnings release both coincided with double‑digit positive moves. Patent protection for ERAS‑0015 through September 2043 and continued global conference visibility frame today’s J.P. Morgan appearance as part of an ongoing investor outreach and RAS/MAPK‑focused pipeline story.
Regulatory & Risk Context
An effective S-3 shelf filed on August 12, 2025 allows Erasca to offer up to $500,000,000 of securities, including an at-the-market component of up to $200,000,000 in common stock, providing flexibility to access capital in multiple formats through August 12, 2028.
Market Pulse Summary
This announcement highlights Erasca’s participation in the 44th J.P. Morgan Healthcare Conference on January 13, 2026, continuing a pattern of active engagement at major investor events. Past updates combined conferences with patent, pipeline and financial disclosures, including cash runway into H2 2028. Investors may watch for any new commentary around the RAS/MAPK-focused pipeline, use of the $500,000,000 shelf, and timing of upcoming clinical data readouts.
Key Terms
ras/mapk pathway medical
oncology medical
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California. Management will present on Tuesday, January 13, 2026, at 1:30 pm Pacific Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
When is Erasca (ERAS) presenting at the J.P. Morgan Healthcare Conference?
How can investors watch Erasca's (ERAS) presentation on January 13, 2026?
Will Erasca (ERAS) hold investor meetings at the 44th J.P. Morgan Healthcare Conference?
Where is the 44th Annual J.P. Morgan Healthcare Conference being held for Erasca's presentation?
What topics will Erasca (ERAS) cover at the January 13, 2026 presentation?
